Obexelimab for the Treatment of IgG4-Related Disease.

Obexelimab significantly delays disease flares and reduces glucocorticoid use in IgG4-related disease, with a hazard ratio of 0.44 and fewer flares compared to placebo.

• Why it matters: IgG4-related disease affects multiple organs and relies on glucocorticoids, which have toxic effects and high relapse rates, highlighting the need for safer, more effective treatments.
• What they did: A phase 3 trial involving 194 patients randomized to receive weekly subcutaneous obexelimab or placebo for 52 weeks, with glucocorticoids tapered off by week 8, assessing time to disease flare and remission.
• The result: Obexelimab extended the time to first flare, increased remission rates to 37.1%, and lowered glucocorticoid rescue doses, demonstrating its potential to improve disease management with fewer adverse events.